Pulmonary Metastasectomy 31 Years After Surgery for Renal Cell Carcinoma

Watanabe, Yui; Harada, Aya; Aoki, Masaya; Kamimura, Go; Wakida, Kazuhiro; Nagata, Toshiyuki; Yokomakura, Naoya; Kariatsumari, Kota; Nakamura, Yoshihiro; Sato, Masami

doi:10.1016/j.athoracsur.2014.07.077

Cited by 6 publications

(9 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A simple physical concept of the process of metastasis is widely pervasive, involving anatomic and mechanical aspects of the vascular and lymphatic system as determinants of how metastasis occurs (hematogenous or lymphatic dissemination). While simple and appealing, this concept is countered by many observations [7]. Different primary tumors exhibit a predilection for particular metastatic sites.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Expert Consensus Document on Pulmonary Metastasectomy

Handy

Bremner

Crocenzi

et al. 2019

The Annals of Thoracic Surgery

152

172

View full text Add to dashboard Cite

When managing nonseminomatous germ cell tumors, contralateral lung abnormalities ≤ 10 mm can be observed if histology of unilateral PM demonstrates complete tumor necrosis. 17. When managing nonseminomatous germ cell tumors, PM is indicated for select patients with limited number of lung abnormalities after first or second-line platin-based chemotherapy suspected of containing viable nonseminomatous cancer and/or malignant transformation of teratoma into non-germ cell cancer. 18. In breast cancer patients, PM can be considered within a MDT construct. Pulmonary metastasectomy literature characteristics Since 1980, greater than 1000 publications addressed pulmonary metastasectomy, without a single randomized controlled trial (RCT). The overwhelming majority is surgical series, usually single institution, and includes single or multiple pathologies. The pool of patients from which metastasectomy patients derive is not reported, allowing no comparative survival analysis. Historical controls are used or metastatic disease survival is assumed to be zero, a contention not supported by the literature. Yet metastasectomy is infrequently performed (1-6.5%) when sizable populations of cancer patients are reported. [1-3] Thus surgical case series manifest inherent selection bias and do not clarify the role of metastasectomy in prolongation of survival or cure. The literature is further hampered by inconsistent or absent description of other local or systemic therapies and variable length of follow up. Finally, the literature fails to distinguish between prognostic (indolent disease which will do well with any or no treatment) or predictive

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Expert Consensus Document on Pulmonary Metastasectomy

Handy

Bremner

Crocenzi

et al. 2019

The Annals of Thoracic Surgery

152

172

View full text Add to dashboard Cite

show abstract

“…Indeed, ~50–60% of the patients will present eventually metastatic disease requiring individual treatment decision [ 7 ]. The median time for tumour relapse following nephrectomy is 15–18 months, with 85% of recurrences occurring within the first 3 years [ 5 ] and 93% within the first 5 years [ 6 ]. Nevertheless, few remarkable cases of late metastatic presentation have been described [ 2 – 5 ].…”

Section: Discussionmentioning

confidence: 99%

“…The median time for tumour relapse following nephrectomy is 15–18 months, with 85% of recurrences occurring within the first 3 years [ 5 ] and 93% within the first 5 years [ 6 ]. Nevertheless, few remarkable cases of late metastatic presentation have been described [ 2 – 5 ]. Shiono et al [ 2 ] reported a case of repeated lung metastasectomy 16, 24 and 25 years after treatment of RCC.…”

Section: Discussionmentioning

confidence: 99%

“…The same author [ 2 ] portrayed a mini review of the scant available literature, encompassing 25 years (1973–1998), where they described another five cases of late presentation of lung metastases from RCC, diagnosed between 20 and 28 years after resection of the primary neoplasm, with survival up to 4 years after metastasectomy. Watanabe and colleagues [ 5 ] recently reported the first case of pulmonary metastasectomy for RCC after an interval of over 30 years since nephrectomy. Their patient was an 82-year-old man in which a large solitary lung metastasis from RCC occurred 31 years after surgical treatment for primary tumour.…”

Section: Discussionmentioning

confidence: 99%

“…After radical nephrectomy, distant metastases are a frequent occurrence, presenting in up to 50% of the cases, with lungs being the most common target of secondary lesions [ 1 ]. Despite late recurrence of metastatic RCC has been previously reported [ 2 – 5 ], the greatest risk of recurrence is instead within the first 5 years following nephrectomy, with incidence as high as 93% [ 6 ]. We herein report an extraordinary case of a solitary lung metastasis from RCC presented 37 years after surgical resection of the primary tumour.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A record-breaking lung metastasis from renal cell carcinoma 37 years after nephrectomy

Tamburrini

Majorino

Duggan

et al. 2017

Journal of Surgical Case Reports

View full text Add to dashboard Cite

Development of distant metastases from renal cell carcinoma (RCC) is a frequent occurrence and, in nearly 95% of the cases, secondary lesions present within 5 years following nephrectomy. We performed a left pneumonectomy for a peri-hilar lung mass in an 81-year-old man with history of kidney cancer, resected 37 years earlier. Histopathological examination revealed a solitary lung metastasis from RCC, relapsed after an extraordinary 37-year time interval. To the best of our knowledge, this remarkable case represents the longest time interval between radical nephrectomy for RCC and the occurrence of a pulmonary metastasis. After an uneventful post-operative recovery, there are no signs of disease recurrence at a 3-year follow-up. The possibility of a lung metastasis should be taken into account in patients with history of RCC who present with pulmonary nodules, even decades after treatment of the primary neoplasm.

show abstract